KR880010764A - 과콜레스테롤혈중 치료용 혼합물 - Google Patents

과콜레스테롤혈중 치료용 혼합물 Download PDF

Info

Publication number
KR880010764A
KR880010764A KR1019880003150A KR880003150A KR880010764A KR 880010764 A KR880010764 A KR 880010764A KR 1019880003150 A KR1019880003150 A KR 1019880003150A KR 880003150 A KR880003150 A KR 880003150A KR 880010764 A KR880010764 A KR 880010764A
Authority
KR
South Korea
Prior art keywords
sucrose
component
gum
composition
polyol polyester
Prior art date
Application number
KR1019880003150A
Other languages
English (en)
Other versions
KR970004956B1 (ko
Inventor
데이비드 브로드더스 챨스
Original Assignee
원본미기재
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 프록터 앤드 갬블 캄파니 filed Critical 원본미기재
Publication of KR880010764A publication Critical patent/KR880010764A/ko
Application granted granted Critical
Publication of KR970004956B1 publication Critical patent/KR970004956B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

내용 없음

Description

과콜레스테롤혈증 치료용 혼합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. (a) 차전자(psyllium seed) 검 또는 차전자 검의 원료; 및 (b) 비흡수성이고 비소화성인 폴리올 폴리에스테르로 이루어짐을 특징으로 하는, 혈중 콜레스테롤 농도를 감소시키는 물질의 조성물.
  2. 제 1 항에 있어서, 폴리올 폴리에스테르 성분 (b)가 슈크로즈 옥타올레에이트, 슈크로즈 옥타리놀레에이트, 슈크로즈 옥타팔미테이트 및 이들의 혼합물인 조성물.
  3. 제 2 항에 있어서, 성분(a);성분(b)의 중량비가 3:1 내지 1:3인 조성물.
  4. 제 1 항에 있어서, 지용성 비타민으로 강화된 조성물.
  5. (a) 차전자 검 또는 차전자 검의 원료;및 (b) 비흡수성이고 비소화성인 폴리올 폴리에스테르;또는 (c)(a) 및 (b)의 혼합물의 안전 유효량을 환자에게 경구 투여함을 특징으로 하여, 혈중 콜레스테롤의 치료를 필요로 하는 환자의 혈중 콜레스테롤을 감소시키는 방법.
  6. 제 5 항에 있어서, 성분(a) 1g 내지 30g 및 성분(b) 5g 내지 50g을 경구 섭취함을 특징으로 하는 방법.
  7. 제 6 항에 있어서, 장기 섭취함을 특징으로 하는 방법.
  8. 제 7 항에 있어서, 매일 섭취함을 특징으로 하는 방법.
  9. 제 8 항에 있어서 하루에 2회 또는 3회에 걸쳐 일정한 간격으로 성분(a) 약 5g 내지 약 15g 및 성분(b) 약 15g 내지 약 50g을 매일 섭취함을 특징으로 하는 방법.
  10. 제 5 항에 있어서, 폴리올 폴리에스테르가 슈크로즈 옥타올레에이트, 슈크로즈 옥타리놀레에이트, 슈크로즈 옥타팔미테이트 및 이들의 혼합물인 방법.
  11. 제 5 항에 있어서, 치료 조성물에 지용성 비타민을 투여함을 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880003150A 1987-03-24 1988-03-24 과콜레스테롤혈증 치료용 혼합물 KR970004956B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US02982 1987-03-24
US07/029,825 US4849222A (en) 1987-03-24 1987-03-24 Mixtures for treating hypercholesterolemia
US029,825 1987-03-24

Publications (2)

Publication Number Publication Date
KR880010764A true KR880010764A (ko) 1988-10-24
KR970004956B1 KR970004956B1 (ko) 1997-04-10

Family

ID=21851092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003150A KR970004956B1 (ko) 1987-03-24 1988-03-24 과콜레스테롤혈증 치료용 혼합물

Country Status (14)

Country Link
US (1) US4849222A (ko)
EP (1) EP0285201B1 (ko)
JP (1) JP2581737B2 (ko)
KR (1) KR970004956B1 (ko)
AT (1) ATE79544T1 (ko)
AU (1) AU620541B2 (ko)
CA (1) CA1314230C (ko)
DE (1) DE3873800T2 (ko)
DK (1) DK167847B1 (ko)
IE (1) IE61404B1 (ko)
IL (1) IL85689A (ko)
NZ (1) NZ223947A (ko)
PH (1) PH26694A (ko)
ZA (1) ZA882061B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679290B1 (ko) * 2005-06-30 2007-02-05 박정휘 Ｈｇｄ­ｓｊ­201 생약 복합제 추출물을 포함하는 비만의예방 및 치료용 조성물

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579752A (en) * 1984-10-29 1986-04-01 At&T Bell Laboratories Enhanced corrosion resistance of metal surfaces
JPH0788318B2 (ja) * 1986-08-06 1995-09-27 三菱レイヨン株式会社 イソブチレンの製造法
US5095008A (en) * 1987-09-14 1992-03-10 The Procter & Gamble Company Cookies containing psyllium
US4950140A (en) * 1987-09-14 1990-08-21 The Procter & Gamble Company Cookies containing psyllium
US5910317A (en) * 1988-01-11 1999-06-08 The Procter & Gamble Company Mixed compositions for treating hypercholesterolemia
US4978529A (en) * 1988-05-25 1990-12-18 Denick Jr John Easily dispersible psyllium compositions
US5149541A (en) * 1988-10-03 1992-09-22 The Procter & Gamble Company Psyllium-containing produces with a distribution of particle size
US5024996A (en) * 1989-12-05 1991-06-18 General Mills, Inc. R-T-E cereal with soluble fibers
US5026689A (en) * 1989-03-29 1991-06-25 General Mills, Inc. R-T-E cereal with psyllium
US5219570A (en) * 1989-08-10 1993-06-15 The Procter & Gamble Company Agglomerated psyllium husk containing edible acid
US6419911B1 (en) 1993-09-17 2002-07-16 Board Of Trustees Of Michigan State University Psyllium containing snack bars, processes for making these, and uses thereof
US5126150A (en) * 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
AU663693B2 (en) * 1990-12-20 1995-10-19 Procter & Gamble Company, The Psyllium and cholestyramine compositions with improved palatability
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US5258181A (en) * 1992-03-02 1993-11-02 The Procter & Gamble Company Compositions containing psyllium
CA2131177C (en) * 1992-03-11 1997-08-05 Hing Cheung Tse Psyllium drink mix compositions containing granulated base
AU3812893A (en) * 1992-03-20 1993-10-21 Procter & Gamble Company, The Anion exchange resin compositions
US5232698A (en) * 1992-06-12 1993-08-03 The Proctor & Gamble Company Psyllium drink mix compositions
US5234916A (en) * 1992-06-12 1993-08-10 The Proctor & Gamble Company Psyllium drink mix compositions
US5338549A (en) * 1992-12-21 1994-08-16 The Procter & Gamble Company Powdered psyllium drink mix compositions containing antioxidant
US5422101A (en) * 1993-05-14 1995-06-06 The Procter & Gamble Company Cholesterol lowering drink mix compositions
US5384144A (en) * 1993-09-17 1995-01-24 Kellogg Company Psyllium enriched pasta products and method for making same
US5384136A (en) * 1993-09-17 1995-01-24 Kellogg Company Psyllium-enriched dough products and method for making the same
US5382443A (en) * 1993-09-17 1995-01-17 Kellogg Company Ready-to-eat cereals containing extruded pre-wetted psyllium
US5955123A (en) * 1996-10-21 1999-09-21 The Procter & Gamble Company Baked compositions comprising psyllium
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6210722B1 (en) 1997-11-07 2001-04-03 Kellogg Company Extruded intermediates containing a soluble fiber and food products containing same
US6123978A (en) 1998-08-31 2000-09-26 Mcneil-Ppc, Inc. Stable salad dressings
AU1712300A (en) 1998-11-05 2000-05-29 Kellogg Company Psyllium enriched baked snack foods
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7238380B2 (en) * 2000-02-22 2007-07-03 Suzanne Jaffe Stillman Water containing soluble fiber
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US20040087658A1 (en) 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
AU2004251636B2 (en) * 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
JP2004352626A (ja) * 2003-05-28 2004-12-16 Asahi Breweries Ltd 植物由来成分を含有する抗コレステロール剤
DE602004017207D1 (de) * 2003-10-22 2008-11-27 Merz Pharma Gmbh & Co Kgaa Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006034465A1 (en) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CN101437539B (zh) * 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PL2200600T3 (pl) 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
EP2085120A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
AU2009328497A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
WO2011000565A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
WO2011000563A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
JP6084931B2 (ja) 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
WO2012171653A1 (en) 2011-06-15 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd)
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
TW201412325A (zh) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
WO2015184008A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018071683A2 (pt) 2016-04-22 2019-02-19 Obi Pharma, Inc. método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
KR20190077103A (ko) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2831854A (en) * 1955-05-24 1958-04-22 Procter & Gamble Method for preparing fatty esters of non-reducing oligosaccharides in the presence of an amide
US3455714A (en) * 1964-09-01 1969-07-15 Hercules Inc Cellulose derivatives of improved dispersibility and process
US3600186A (en) * 1968-04-23 1971-08-17 Procter & Gamble Low calorie fat-containing food compositions
US3579548A (en) * 1968-05-10 1971-05-18 Procter & Gamble Triglyceride esters of alpha-branched carboxylic acids
US3954976A (en) * 1973-12-14 1976-05-04 The Procter & Gamble Company Pharmaceutical compositions for inhibiting absorption of cholesterol
US3963699A (en) * 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US4034083A (en) * 1975-11-03 1977-07-05 The Procter & Gamble Company Compositions for inhibiting absorption of cholesterol
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
IE44458B1 (en) * 1976-02-12 1981-12-02 Procter & Gamble Compositions for treating hypercholesterolemia
US4005196A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Vitaminized compositions for treating hypercholesterolemia
US4241054A (en) * 1978-12-08 1980-12-23 The Procter & Gamble Company Detoxifying lipophilic toxins
US4264583A (en) * 1979-07-25 1981-04-28 The Procter & Gamble Company Gallstone dissolution compositions and method
US4382924A (en) * 1980-06-25 1983-05-10 The Procter & Gamble Company Palatable composition containing oil or oil-like materials
DE3027611A1 (de) * 1980-07-21 1982-02-18 Bayer Ag, 5090 Leverkusen Di- und oligo-1,2,4-triazolidin-3,5-dione und verfahren zu ihrer herstellung
US4321263A (en) * 1980-09-30 1982-03-23 Rowell Laboratories, Inc. Psyllium compositions
US4461782A (en) * 1982-02-16 1984-07-24 The Procter & Gamble Company Low calorie baked products
US4517360A (en) * 1983-06-23 1985-05-14 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters using carbonate catalysts
US4518772A (en) * 1983-06-23 1985-05-21 The Proctor & Gamble Company Synthesis of higher polyol fatty acid polyesters using high soap:polyol ratios

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679290B1 (ko) * 2005-06-30 2007-02-05 박정휘 Ｈｇｄ­ｓｊ­201 생약 복합제 추출물을 포함하는 비만의예방 및 치료용 조성물

Also Published As

Publication number Publication date
US4849222A (en) 1989-07-18
DE3873800T2 (de) 1993-01-14
IL85689A (en) 1993-05-13
DK167847B1 (da) 1993-12-27
PH26694A (en) 1992-09-15
JP2581737B2 (ja) 1997-02-12
JPS6426A (en) 1989-01-05
ATE79544T1 (de) 1992-09-15
EP0285201B1 (en) 1992-08-19
KR970004956B1 (ko) 1997-04-10
DE3873800D1 (de) 1992-09-24
EP0285201A3 (en) 1990-01-24
DK162488D0 (da) 1988-03-24
ZA882061B (en) 1988-09-14
IE880870L (en) 1988-09-24
AU1352188A (en) 1988-09-22
AU620541B2 (en) 1992-02-20
IE61404B1 (en) 1994-11-02
DK162488A (da) 1988-09-25
NZ223947A (en) 1991-02-26
EP0285201A2 (en) 1988-10-05
CA1314230C (en) 1993-03-09

Similar Documents

Publication Publication Date Title
KR880010764A (ko) 과콜레스테롤혈중 치료용 혼합물
Drent et al. First clinical studies with orlistat: a short review
AU7848187A (en) Pharmaceutical formulations
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
GB9519661D0 (en) Fatty acid treatment
ES2033464T3 (es) Composiciones de relleno que contienen psyllium.
KR890003391A (ko) 칼슘 보충제
ATE6645T1 (de) Dibenzoxazepin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US5116610A (en) Compositions for treating hypercholesterolemia
ATE56148T1 (de) Orales dextran enthaltende zusammensetzungen.
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
KR920702225A (ko) 약학 조성물
KR930003913A (ko) 덱스트로메토르판의 진해효과를 증진시키기 위한 방법 및 약제학적 조성물
KR880002521A (ko) 약제 제형
DE3879489D1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
US5910317A (en) Mixed compositions for treating hypercholesterolemia
Friedman et al. Renal excretion of digitoxin as an indicator of (1) adequate and (2) excessive digitalization
Schottstaedt et al. Natural history and course of malignant hypertension
JPS6440455A (en) 2-methyl-2-benzoylamino-3-(3',4'-dihydroxyphenyl)propionic acid and remedy for circulatory organ disease, hair tonic and cosmetic containing said compound as active ingredient
KR930700109A (ko) 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘
KR880012206A (ko) 구강질환 치료 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee